Table 1.
Prevalence of abnormal QRS complexes and ventricular tachycardia before and after flecainide infusion
| AF group | Control group | ||||
|---|---|---|---|---|---|
| Abnormal QRS complex | Consecutive abnormal QRS complexes | Abnormal QRS complex | Consecutive abnormal QRS complexes | ||
| Day 0 | Before treatment | 1 (1) | – | – | – |
| Flecainide | – | – | – | – | |
| Day 3 | Before treatment | 1 (20) | – | – | – |
| Flecainide | – | – | – | – | |
| Day 9 | Before treatment | 2 (6/12*) | – | – | – |
| Flecainide | 3 (2/3/6) | – | 1 (1) | – | |
| Day 27 | Before treatment | 1 (1) | – | – | – |
| Flecainide | 4 (1/3/7*/12*) | 2 (1/4#) | – | – | |
| Day 55 | Before treatment | 2 (2/8*) | 1 (1) | – | – |
| Flecainide | 2 (10*/16*) | 2 (1/1#) | – | – | |
Number of horses experiencing single or coupled abnormal QRS complexes and number of horses experiencing episodes of consecutive abnormal QRS complexes in separate columns. The number of abnormal complexes and episodes of consecutive abnormal complexes are specified in brackets with the number for each horse separated by “/”. * indicates that some of the abnormal QRS complexes are coupled. # indicates that detomidine was administered. AF = atrial fibrillation; Before = 30 min before flecainide infusion; Flecainide = during and 30 min after flecainide infusion.